




RealRate

PHARMACEUTICAL 2020

Salarius Pharmaceuticals Inc. Rank 125 of 358





RealRate

PHARMACEUTICAL 2020

Salarius Pharmaceuticals Inc. Rank 125 of 358



The relative strengths and weaknesses of Salarius Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Salarius Pharmaceuticals Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 169% points. The greatest weakness of Salarius Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 131%, being 95% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	4,695
Cost of Goods Sold	0
Intangible Assets	8,866
Liabilities, Current	1,791
Liabilities, Non-Current	0
Other Assets	309
Other Compr. Net Income	0
Other Expenses	-1,311
Other Liabilities	1,523
Other Net Income	17
Other Revenues	3,465
Property and Equipment	25
Research and Development	4,019
Selling, General and Administrative Expense	7,711

Output Variable	Value in 1000 USD
Assets	13,894
Liabilities	3,314
Expenses	10,419
Revenues	3,465
Stockholders Equity	10,581
Net Income	-6,936
Comprehensive Net Income	-6,936
Economic Capital Ratio	131%